[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cranial-nerve-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cranial-nerve-disorder":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100374101","phase-1-high-dose-steroid-therapy-prednisone-or-methylprednisolone-for-the-improvement-of-symptoms-of-late-radiation-associated-lower-cranial-neuropathy-in-oropharyngeal-cancer-survivors-100374101",false,"NCT04151082","High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors","Stop LCNP: High Dose Steroid Therapy for Late Radiation-Associated Lower Cranial Neuropathy: A Phase I\u002FII Dose Finding Trial and Data Registry","Inclusion Criteria:\n\n* INCLUSION CRITERIA FOR CLINICAL TRIAL: Disease free adult survivors of oropharyngeal cancer\n* INCLUSION CRITERIA FOR CLINICAL TRIAL: Treated with radiotherapy \\>= 2 years post treatment (disease status per surveillance imaging and clinical surveillance)\n* INCLUSION CRITERIA FOR CLINICAL TRIAL: Late radiation-associated lower cranial neuropathy of XII with or without X nerve (LCNP cases will be considered therapy-related when imaging, physical examination, and\u002For biopsy fail to demonstrate structural or malignant source)\n* INCLUSION CRITERIA FOR CLINICAL TRIAL: Willing and able to return for assessment post-steroid therapy\n* INCLUSION CRITERIA FOR CLINICAL TRIAL: Able to complete symptom survey (MD Anderson Symptom Inventory - Head and Neck \\[MDASI-HN\\]) in validated languages: English, simplified Chinese, Filipino, Greek, Japanese, Korean, Russian, Spanish, Taiwanese\n* INCLUSION CRITERIA FOR REGISTRY: Disease-free adult survivors of head and neck cancer\n* INCLUSION CRITERIA FOR REGISTRY: \\>= 2 years post treatment (disease status per surveillance imaging and clinical surveillance)\n* INCLUSION CRITERIA FOR REGISTRY: Late lower cranial neuropathy of XII with or without X nerve (LCNP cases will be considered therapy-related when imaging, physical examination, and\u002For biopsy fail to demonstrate structural or malignant source)\n* INCLUSION CRITERIA FOR REGISTRY: Able to complete symptom survey (MDASI-HN) in validated languages: English, simplified Chinese, Filipino, Greek, Japanese, Korean, Russian, Spanish, Taiwanese\n\nExclusion Criteria:\n\n* EXCLUSION CRITERIA FOR CLINICAL TRIAL: Uncontrolled diabetes\n* EXCLUSION CRITERIA FOR CLINICAL TRIAL: Uncontrolled hypertension (systolic \\> 160; diastolic \\> 90)\n* EXCLUSION CRITERIA FOR CLINICAL TRIAL: Known gastrointestinal ulcer\n* EXCLUSION CRITERIA FOR CLINICAL TRIAL: History of psychosis\n* EXCLUSION CRITERIA FOR CLINICAL TRIAL: Pregnant women\n* EXCLUSION CRITERIA FOR CLINICAL TRIAL: Untreated or treatment refractory obstructive pharyngoesophageal stricture\n* EXCLUSION CRITERIA FOR CLINICAL TRIAL: Known history or diagnosis of bipolar disorder\n* EXCLUSION CRITERIA FOR CLINICAL TRIAL: History of surgery near hypoglossal nerve path\n* EXCLUSION CRITERIA FOR REGISTRY: Uncontrolled diabetes\n* EXCLUSION CRITERIA FOR REGISTRY: Uncontrolled hypertension (systolic \\> 160; diastolic \\> 90)\n* EXCLUSION CRITERIA FOR REGISTRY: Known gastrointestinal ulcer\n* EXCLUSION CRITERIA FOR REGISTRY: History of psychosis\n* EXCLUSION CRITERIA FOR REGISTRY: Pregnant women\n* EXCLUSION CRITERIA FOR REGISTRY: Untreated or treatment refractory obstructive pharyngoesophageal stricture\n* EXCLUSION CRITERIA FOR REGISTRY: Known history or diagnosis of bipolar disorder","ALL","18 Years",{"count":19,"type":20},35,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This phase I\u002FII trial studies the side effect and best dose of steroid therapy (prednisone or methylprednisolone) in improving symptoms of late radiation-associated lower cranial neuropathy in oropharyngeal cancer survivors. Steroid therapy with prednisone or methylprednisolone may help to improve symptoms associated with late radiation-associated lower cranial neuropathy.",[27,28,29],"Cranial Nerve Disorder","Head and Neck Carcinoma","Oropharyngeal Carcinoma","RECRUITING","2026-06-24",{"date":33,"type":34},"2026-06-26","ACTUAL",{"date":36,"type":34},"2019-10-16",{"date":38,"type":20},"2027-07-31",{"name":40,"class":41},"M.D. Anderson Cancer Center","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":42},"100306502","phase-2-gadolinium-and-ferumoxytol-mri-in-diagnosing-patients-with-abnormalities-in-the-central-nervous-system-100306502","NCT03270059","Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System","The Feasibility of Steady State CBV Mapping Using Ferumoxytol Immediately After Gadolinium Enhanced MRI of the CNS","Inclusion Criteria:\n\n* Subjects must have one of the following:\n\n  * Neurological findings (i.e. headache, loss of consciousness, paresis, cranial neuropathy, seizures, etc.)\n  * Radiological abnormalities in the brain (neoplastic or non-neoplastic in nature)\n  * Neoplastic process elsewhere in the body that may affect the brain (i.e. possible metastasis, vascular compromise, treatment related changes, etc.)\n* Subjects must be able to undergo MRI imaging without anesthesia\n* Subjects must be at least 10 years of age\n* All subjects, or their legal guardians, must sign a written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization in accordance with institutional guidelines\n* Sexually active women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; surgical intervention i.e. tubal ligation or vasectomy; post-menopausal \\\u003C 6 months; or abstinence) for at least two months after each cycle of the study; should a female become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\n\nExclusion Criteria:\n\n* Subjects with clinically significant signs of uncal herniation, such as acute pupillary enlargement, rapidly developing motor changes (over hours), or rapidly decreasing level of consciousness, are not eligible\n* Subjects with known allergic or hypersensitivity reactions to parenteral iron, parenteral dextran, parenteral iron-dextran, or parenteral iron-polysaccharide preparations (Ferumoxytol Investigator's Drug Brochure, 2009); subjects with significant drug or other allergies or autoimmune diseases may be enrolled at the investigator's discretion\n* Subjects who are pregnant or lactating or who suspect they might be pregnant\n* Subjects who have a contraindication for MRI: metal in their bodies (a cardiac pacemaker or other incompatible device), are severely agitated, or have an allergy to gadolinium containing contrast material\n* Subjects with known iron overload (genetic hemochromatosis); in subjects with a family history of hemochromatosis, hemochromatosis must be ruled out prior to study entry with normal values of the following blood tests: transferrin saturation (TS) test and serum ferritin (SF) test; all associated costs will be paid by the study\n* Subject who have received ferumoxytol within 3 weeks of study entry\n* Subjects with three or more drug allergies from separate drug classes","10 Years",{"count":52,"type":20},150,[24],"This phase II trial studies how well gadolinium and ferumoxytol magnetic resonance imaging (MRI) work in diagnosing patients with abnormalities in the central nervous system. Diagnostic procedures, such as gadolinium and ferumoxytol MRI, may help find and diagnose abnormalities in the central nervous system.",[56,27,57],"Central Nervous System Neoplasm","Metastatic Malignant Neoplasm in the Brain","2026-02-25",{"date":60,"type":34},"2026-02-27",{"date":62,"type":34},"2017-10-06",{"date":64,"type":20},"2028-12-15",{"name":66,"class":41},"OHSU Knight Cancer Institute",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":73,"sex":16,"minAge":17,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":42},"100603326","cranial-nerve-functions-in-behets-disease-and-their-relationship-with-clinical-parameters-100603326","NCT07135063","Cranial Nerve Functions in Behçet's Disease and Their Relationship With Clinical Parameters","Inclusion Criteria:\n\n* Aged 18-75\n* Diagnosed with BD according to ACR\u002FEULAR 2013 criteria (patient group)\n* Healthy with no relevant medical history (control group)\n\nExclusion Criteria:\n\n* Conditions affecting CN assessment (e.g., facial trauma, surgery, radiotherapy)\n* Other rheumatologic or autoimmune diseases\n* Psychiatric disorders, alcohol\u002Fsubstance abuse\n* Pregnant women\n* Use of pacemakers or recent botox to masseter muscle",true,"75 Years",{"count":76,"type":20},60,"OBSERVATIONAL","The goal of this study is to find out whether cranial nerves are affected in people with Behçet's Disease (BD), and how this might relate to other disease features. Cranial nerves control important functions such as vision, facial movement, hearing, swallowing, and balance.\n\nThe main questions this study will address are:\n\n* Do people with BD have changes in cranial nerve function compared to healthy individuals?\n* Are these changes linked to disease duration, symptoms, or lab results?\n\nParticipants will:\n\n* Answer questions about their medical history and BD symptoms\n* Complete questionnaires on daily function, mood, and autonomic symptoms\n* Have a clinical examination of all 12 cranial nerves\n* Undergo non-invasive electrical tests to assess nerve function This study will not involve any medications. All procedures will be completed in one visit.",[80,27],"Behcet Disease","NOT_YET_RECRUITING","2025-08-13",{"date":84,"type":34},"2025-08-21",{"date":86,"type":20},"2025-10",{"date":88,"type":20},"2026-09",{"name":90,"class":41},"Marmara University"]